Literature DB >> 28831690

Effects of risk factors for and components of metabolic syndrome on the quality of life of patients with systemic lupus erythematosus: a structural equation modeling approach.

Jeong-Won Lee1, Ji-Hyoun Kang1, Kyung-Eun Lee1, Dong-Jin Park1, Seong Wook Kang2, Seung-Ki Kwok3, Seong-Kyu Kim4, Jung-Yoon Choe4, Hyoun-Ah Kim5, Yoon-Kyoung Sung6, Kichul Shin7, Sang-Il Lee8, Chang Hoon Lee9, Sung Jae Choi10, Shin-Seok Lee11.   

Abstract

PURPOSE: This study assessed the relationships among the risk factors for and components of metabolic syndrome (MetS) and health-related quality of life (HRQOL) in a hypothesized causal model using structural equation modeling (SEM) in patients with systemic lupus erythematosus (SLE).
METHODS: Of the 505 SLE patients enrolled in the Korean Lupus Network (KORNET registry), 244 had sufficient data to assess the components of MetS at enrollment. Education level, monthly income, corticosteroid dose, Systemic Lupus Erythematosus Disease Activity Index, Physicians' Global Assessment, Beck Depression Inventory, MetS components, and the Short Form-36 at the time of cohort entry were determined. SEM was used to test the causal relationship based on the Analysis of Moment Structure.
RESULTS: The average age of the 244 patients was 40.7 ± 11.8 years. The SEM results supported the good fit of the model (χ 2 = 71.629, p = 0.078, RMSEA 0.034, CFI 0.972). The final model showed a direct negative effect of higher socioeconomic status and a positive indirect effect of higher disease activity on MetS, the latter through corticosteroid dose. MetS did not directly impact HRQOL but had an indirect negative impact on it, through depression.
CONCLUSIONS: In our causal model, MetS risk factors were related to MetS components. The latter had a negative indirect impact on HRQOL, through depression. Clinicians should consider socioeconomic status and medication and seek to modify disease activity, MetS, and depression to improve the HRQOL of SLE patients.

Entities:  

Keywords:  Depression; Metabolic syndrome; Quality of life; Systemic lupus erythematosus

Mesh:

Year:  2017        PMID: 28831690     DOI: 10.1007/s11136-017-1689-z

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  42 in total

1.  Impact of Therapy on Metabolic Syndrome in Young Adult Premenopausal Female Lupus Patients: Beneficial Effect of Antimalarials.

Authors:  Luciana F Muniz; Rosa M R Pereira; Thiago F Silva; Eloisa Bonfá; Eduardo F Borba
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-09       Impact factor: 4.794

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients.

Authors:  S Demir; B Artim-Esen; Y Şahinkaya; Ö Pehlivan; N Alpay-Kanıtez; A Omma; B Erer; S Kamalı; A Gül; O Aral; L Öcal; M İnanç
Journal:  Lupus       Date:  2015-09-08       Impact factor: 2.911

4.  Health-related quality of life in metabolic syndrome: The Korea National Health and Nutrition Examination Survey 2005.

Authors:  Sang Shin Park; Yeong Sook Yoon; Sang Woo Oh
Journal:  Diabetes Res Clin Pract       Date:  2010-12-04       Impact factor: 5.602

5.  Metabolic syndrome and health-related quality of life among U.S. adults.

Authors:  Earl S Ford; Chaoyang Li
Journal:  Ann Epidemiol       Date:  2008-03       Impact factor: 3.797

6.  Sex differences in the association of socioeconomic status with obesity.

Authors:  Jane Wardle; Jo Waller; Martin J Jarvis
Journal:  Am J Public Health       Date:  2002-08       Impact factor: 9.308

7.  Metabolic syndrome in Argentinean patients with systemic lupus erythematosus.

Authors:  V Bellomio; A Spindler; E Lucero; A Berman; R Sueldo; H Berman; M Santana; M J Molina; V Góngora; G Cassano; S Paira; V Saurit; S Retamozo; G Retamozo; A Alvarellos; F Caerio; P Alba; M Gotero; E J Velozo; F Ceballos; E Soriano; L Catoggio; M A García; A Eimon; S Agüero
Journal:  Lupus       Date:  2009-10       Impact factor: 2.911

8.  Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico.

Authors:  A M Negrón; M J Molina; A M Mayor; V E Rodríguez; L M Vilá
Journal:  Lupus       Date:  2008-04       Impact factor: 2.911

9.  Socio-demographic and psychosocial factors are associated with features of the metabolic syndrome. The Women's Health in the Lund Area (WHILA) study.

Authors:  J Lidfeldt; P Nyberg; C Nerbrand; G Samsioe; B Scherstén; C D Agardh
Journal:  Diabetes Obes Metab       Date:  2003-03       Impact factor: 6.577

10.  Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007.

Authors:  Soo Lim; Hayley Shin; Jung Han Song; Soo Heon Kwak; Seon Mee Kang; Ji Won Yoon; Sung Hee Choi; Sung Il Cho; Kyong Soo Park; Hong Kyu Lee; Hak Chul Jang; Kwang Kon Koh
Journal:  Diabetes Care       Date:  2011-04-19       Impact factor: 19.112

View more
  4 in total

Review 1.  Anxiety and Mood Disorders in Systemic Lupus Erythematosus: Current Insights and Future Directions.

Authors:  Annaliese Tisseverasinghe; Christine Peschken; Carol Hitchon
Journal:  Curr Rheumatol Rep       Date:  2018-11-12       Impact factor: 4.592

2.  Multidisciplinary care in patients with systemic lupus erythematosus: a randomized controlled trial in China.

Authors:  Le Zhang; Shikai Geng; Liping Qian; Shuang Ye; Xiaodong Wang; Guohong Lu; Yang Ding; Ting Li
Journal:  Int J Clin Pharm       Date:  2019-06-25

3.  Associations of metabolic syndrome in SLE.

Authors:  Diane Apostolopoulos; Fabien Vincent; Alberta Hoi; Eric Morand
Journal:  Lupus Sci Med       Date:  2020-11

4.  Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study.

Authors:  Yoshia Miyawaki; Sayaka Shimizu; Yusuke Ogawa; Ken-Ei Sada; Yu Katayama; Yosuke Asano; Keigo Hayashi; Yuriko Yamamura; Sumie Hiramatsu-Asano; Keiji Ohashi; Michiko Morishita; Haruki Watanabe; Mariko Takano-Narazaki; Yoshinori Matsumoto; Nobuyuki Yajima; Ryusuke Yoshimi; Yasuhiro Shimojima; Shigeru Ohno; Hiroshi Kajiyama; Kunihiro Ichinose; Shuzo Sato; Michio Fujiwara; Hajime Yamazaki; Yosuke Yamamoto; Jun Wada; Shunichi Fukuhara
Journal:  Arthritis Res Ther       Date:  2021-03-10       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.